Search
News & Events
Early Years Initiative an unprecedented commitment to youngest West AustraliansMinderoo Foundation and The Kids Research Institute Australia are proud to partner with the Western Australian Government on an unprecedented $49.3 million commitment to
News & Events
Study unlocks new knowledge about the role of immune cells in asthma flare-upsFlare-ups of asthma are usually brought on by respiratory infections, such as the common cold, and are one of the most common reasons for a child to miss school or require emergency care.
News & Events
The Kids welcomes Minderoo investment in early child developmentThe Kids has congratulated Andrew & Nicola Forrest on their visionary commitment to develop a new blueprint for optimal child development in Aust & beyond.
Over 20 years Professor Harvey Oates has made financial contributions to The Kids totaling over 6 figures, as well as sitting on the board for 16 years.
Little or large, every donation made to The Kids Research Institute Australia is precious.
Discover the latest community involvement opportunities from across the Institute.
Telethon Kids Institute is leading the development of a National Vaccine Platform for conducting trials to improve protection from diseases that can prevented with vaccines. We are seeking people from Culturally and Linguistically Diverse backgrounds to join our new Vaccines Community Advisory Group.
We are seeking expressions of interest from community members with children between the ages of 0-5 years old to join our Community Advisory Group.
Research
The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness programTranscriptional cofactors of the ETO family are recurrent fusion partners in acute leukemia. We characterized the ETO2 regulome by integrating transcriptomic and chromatin binding analyses in human erythroleukemia xenografts and controlled ETO2 depletion models. We demonstrate that beyond its well-established repressive activity, ETO2 directly activates transcription of MYB, among other genes.
Research
A biobank of pediatric patient-derived-xenograft models in cancer precision medicine trial MAPPYACTS for relapsed and refractory tumorsPediatric patients with recurrent and refractory cancers are in most need for new treatments. This study developed patient-derived-xenograft (PDX) models within the European MAPPYACTS cancer precision medicine trial.